Key result
ApoE ε4 carrier status was associated with lower 3-month MoCA scores in older patients with ICAS.
Why the study?
Whether apolipoprotein E (ApoE) ε4 carrier status is associated with 3-month cognitive performance and structural brain injury in older patients with intracranial atherosclerotic stenosis (ICAS) needed investigation.
Is apolipoprotein E (ApoE) ε4 carrier status associated with poorer 3-month cognitive performance and increased structural brain injury in older patients with intracranial atherosclerotic stenosis?
Cohort (n=150)
No
Is apolipoprotein E (ApoE) ε4 carrier status associated with poorer 3-month cognitive performance and increased structural brain injury in older patients with intracranial atherosclerotic stenosis?
In elderly patients with intracranial atherosclerotic stenosis, ApoE ε4 carriage is associated with worse 3-month global cognitive performance and greater white matter hyperintensity burden.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open ApoE ε4 utility for cognitive risk stratification in intracranial stenosis.
To investigate whether apolipoprotein E (ApoE) ε4 carrier status is associated with 3-month cognitive performance and structural brain injury in older patients with intracranial atherosclerotic stenosis (ICAS). This prospective cohort study enrolled 150 patients aged ≥60 years with ICAS (≥50% stenosis on MRA/CTA). ApoE ε4 carriers (n = 21, 14.0%) were compared with noncarriers. Primary outcome was 3-month Montreal Cognitive Assessment (MoCA) score. Secondary cognitive outcome was 3-month Mini-Mental State Examination (MMSE) score. White matter hyperintensity burden defined as Fazekas score ≥2 was primary structural outcome. Multivariable linear and logistic regression models adjusted for age, sex, education, symptomatic ICAS, hypertension, and diabetes. Firth’s penalized logistic regression addressed near-complete separation in the Fazekas analysis. ApoE ε4 carrier status was associated with lower 3-month MoCA (β = -1.887, 95% CI: -3.359 to -0.415, P = 0.013) and MMSE scores (β = -1.931, 95% CI: -3.177 to -0.685, P = 0.003). The structural analysis yielded association with Fazekas score ≥2 (Firth OR = 6.144, 95% CI: 1.331 to 59.563, P = 0.017), although this estimate was imprecise and hypothesis-generating. Additional adjustment for baseline cognitive scores changed the cognitive estimates. In older patients with ICAS, ApoE ε4 carriage is associated with poorer 3-month global cognitive performance. Given the modest sample size, few ε4 carriers, short follow-up, and single-center design, larger multicenter studies with longer follow-up are needed to clarify the longitudinal relationship between ApoE ε4 status and cognitive change.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) conducted a cohort in Intracranial atherosclerotic stenosis (ICAS) (n=150). ApoE ε4 carrier status vs. ApoE ε4 noncarriers was evaluated on 3-month Montreal Cognitive Assessment (MoCA) score (β = -1.887, 95% CI -3.359 to -0.415, p=0.013). ApoE ε4 carrier status was associated with lower 3-month MoCA scores in older patients with ICAS.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: